In an interview on CNBC’s Mad Money, Robert Davis said Merck (MRK) is starting to see new launches driving growth. The company sees $70B in commercial opportunities by the mid 2030’s. It has one of the deepest, broadest pipelines it has ever had, Davis said. “We’re not trying to compete with the monoclonals. We want to expand that market,” he noted.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK: